India’s obesity crisis fuels a $2.6 bn drug race as pharma firms rush to launch affordable semaglutide generics, aiming to ...

Danish pharmaceutical company Novo Nordisk is set to launch its anti-diabetes and weight-loss drug Wegovy in India, aiming to ...

“Even as we face patent expiration for Semaglutide, we’ll probably ... addressing a question on the brand’s potential India ...

India's anti-obesity drug market shows significant growth. It has increased fourfold in five years. Lifestyle diseases and ...

Hundreds of thousands of people across the country are taking Semaglutide or Tirzepatide. Many of those people get their medication through a compounding pharmacy as opposed to getting the brand ...

The active ingredient in Wegovy is semaglutide, which is likely to go off-patent in 2026 in India. Wegovy and Lilly's Mounjaro belong to the same class of treatments called GLP-1 agonists ...

During past shortages, high demand and costs for brand-name semaglutide products have led people to use compounded semaglutide. Novo Nordisk, the pharmaceutical company that currently produces FDA ...

The legal battle over who can make and distribute a weight loss ingredient is brewing, and an Edmond telehealth provider is ...

Semaglutide brand names include Ozempic, Rybelus, and Wegovy, all made by Novo Nordisk, and Mounjaro from Eli Lilly. The study, led by the Centers for Disease Control and Prevention and Cambridge ...

In India, there were 32 centres and 788 people enrolled. Semaglutide was initially approved in June 2021 for chronic weight management in those with obesity or overweight and at least one weight ...

A recent clinical trial, led by UNC School of Medicine researchers Dr. John Buse and Dr. Matthew Cavender, found that the oral form of semaglutide significantly reduces the risk of cardiovascular ...